Listening to Mom 2: Neural, Clinical and Language Outcomes

November 20, 2023 updated by: Katherine E Travis, PhD, Stanford University

Listening to Mom in the Neonatal Intensive Care Unit (NICU): Neural, Clinical and Language Outcomes

The purpose of this study is to examine whether playing recordings of a mother's voice to her infant while in the hospital nursery is an effective treatment for promoting healthy brain and language development in infants born preterm.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

Children born preterm are at-risk for developmental language delays. Language problems in preterm children are thought to be related to neurobiological factors, including injuries to white matter structures of the brain and environmental factors, including decreased exposure to maternal speech in the hospital nursery. There is evidence to suggest that maternal speech input may be important for promoting healthy brain and language development.

Participants will be randomly assigned to one of two study groups. Each infant has a 50% chance of being assigned to the group that will listen to a recording of his/her mother's voice and a 50% chance of being assigned to the group that will not be played a voice recording. Mother's of participating infants will have her voice recorded as she reads a common children's storybook. Recordings will be played to infants each day until s/he is discharged from the hospital. To assess the long term impacts of this treatment, research participants and their families will be asked to return for follow-up visiting to perform an MRI brain scan and complete questionnaires and test that assess language development. Follow-up visit occur when infants are between 12 to 18 months of age.

Study Type

Interventional

Enrollment (Actual)

57

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • California
      • Palo Alto, California, United States, 94304
        • Stanford University - Lucile Packard Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 months to 7 months (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Infants born preterm at Stanford Children's Hospital between 24 0/7 - 31 6/7 weeks gestational age

Exclusion Criteria:

  • Congenital anomalies
  • Recognizable malformation syndromes
  • Active seizure disorders
  • History of Central Nervous System infections
  • Hydrocephalus
  • Major sensori-neural hearing loss
  • Likelihood to be transferred from NICU to alternate care facility or home environment prior to 36 weeks PMA and/or brain MRI scan
  • Intraventricular Hemorrhage Grades III-IV
  • Cystic periventricular leukomalacia (PVL)
  • Surgical treatment for necrotizing enterocolitis
  • Small for gestational age (SGA) <3 percentile and/or Intra-uterine growth restriction (IUGR) no head sparing
  • Twin-to-twin transfusions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Language Treatment Arm
An infant participant randomized to the language treatment arm will be played recordings of his/her mother's voice 2-3 hours daily in the intermediate care nursery until discharge.
Recording of a mother's voice reading a children's storybook.
Sham Comparator: Control Treatment Arm
An infant participant randomized to the control treatment arm will receive standard of care. Standard of care does not include being played recordings of his/her mother's voice while admitted to the intermediate care nursery. However, an infant randomized to the control treatment will have the same auditory equipment placed in his/her isolette or crib as an infant randomized to the Language Treatment Arm.
Standard of Care
Other Names:
  • Standard of Care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Standard and Raw Scores of Receptive and Expressive Language on MacArthur-Bates Communicative Development Inventory (CDI): Words and Sentences
Time Frame: 18 month follow-up adjusted age for preterm birth
Parent questionnaire of receptive and expressive language skills. Will be used to assess the long-term impact of intervention on language outcomes. Standard scores are based on percentiles for age and sex and range from <1 to 99th percentile. Raw scores range from 0 to 680. Both higher standard scores and raw scores indicate better performance.
18 month follow-up adjusted age for preterm birth

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
White matter mean diffusivity
Time Frame: Assessed at near-term equivalent age MRI scan (approx. 36-37 weeks postmenstrual age) or at time of hospital discharge, whichever comes first
Diffusion MRI metric that measures the average rate of water diffusion. It is used to assess white matter development and structure.
Assessed at near-term equivalent age MRI scan (approx. 36-37 weeks postmenstrual age) or at time of hospital discharge, whichever comes first
Fractional Anisotropy of white matter tracts of the brain
Time Frame: Assessed at near-term equivalent age MRI scan (approx. 36-37 weeks postmenstrual age) or at time of hospital discharge, whichever comes first
Diffusion MRI metric that measures the directionality of water diffusion in the brain. It is used to assess white matter development and structure.
Assessed at near-term equivalent age MRI scan (approx. 36-37 weeks postmenstrual age) or at time of hospital discharge, whichever comes first
White matter mean diffusivity
Time Frame: Assessed at 12 month follow-up MRI
Diffusion MRI metric that measures the average rate of water diffusion. It is used to assess white matter development and structure
Assessed at 12 month follow-up MRI
Fractional Anisotropy of white matter tracts of the brain
Time Frame: Assessed at 12 month follow-up MRI
Diffusion MRI metric that measures the directionality of water diffusion in the brain. It is used to assess white matter development and structure.
Assessed at 12 month follow-up MRI
Score on MacArthur-Bates Communicative Development Inventories: Words and Gestures
Time Frame: 12 month follow-up adjusted for preterm birth
Parent questionnaire of receptive and expressive language skills. Will be used to assess the long-term impact of intervention on language outcomes. Standard scores are based on percentiles for age and sex and range from <1 to 99th percentile. Raw scores range from 0 to 396. Both higher standard scores and raw scores indicate better performance.
12 month follow-up adjusted for preterm birth
Number of significant apnea, bradycardia and desaturation events requiring stimulation
Time Frame: measured daily and beginning at start of treatment and until end of treatment, approximately 37-40 weeks PMA
Reflects degree of cardiorespiratory stability
measured daily and beginning at start of treatment and until end of treatment, approximately 37-40 weeks PMA
Time (days) to full oral feed
Time Frame: measured daily and beginning at start of treatment and until end of treatment, approximately 37-40 weeks PMA
days until 100 % of nutrition administered orally
measured daily and beginning at start of treatment and until end of treatment, approximately 37-40 weeks PMA
Average daily weight gain
Time Frame: measured daily and beginning at start of treatment and until end of treatment, approximately 37-40 weeks PMA
measured as weight gain per day
measured daily and beginning at start of treatment and until end of treatment, approximately 37-40 weeks PMA

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Katherine E Travis, PhD, Stanford University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 25, 2019

Primary Completion (Estimated)

August 1, 2025

Study Completion (Estimated)

March 1, 2026

Study Registration Dates

First Submitted

December 6, 2019

First Submitted That Met QC Criteria

December 6, 2019

First Posted (Actual)

December 10, 2019

Study Record Updates

Last Update Posted (Estimated)

November 21, 2023

Last Update Submitted That Met QC Criteria

November 20, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Premature Birth

Clinical Trials on Language Treatment

3
Subscribe